Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
2012 · Cancer Chemotherapy and Pharmacology · 262 citations
https://doi.org/10.1007/s00280-011-1817-3
B
Bei Wang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
9
Papers
476
Citations
6
h-index
6
i10-index
Bei Wang is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Monoclonal and Polyclonal Antibodies Research & Mosquito-borne diseases and control. The author has an h-index of 6, co-authored 8 publications.
ORCID: 0009-0002-7992-6414Papers by this author
worksAn Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer
2013 · Clinical Pharmacokinetics · 43 citations
https://doi.org/10.1007/s40262-013-0060-y
Identification of indocyanine green as a STT3B inhibitor against mushroom α-amanitin cytotoxicity
2023 · Nature Communications · 29 citations
https://doi.org/10.1038/s41467-023-37714-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat